With increasing scrutiny from regulatory bodies and a rising tide of product recalls, companies must choose between two approaches: the carrot, which symbolises incentives for quality improvement, and the stick, representing punitive measures for non-compliance. NSF experts look at the historical context, current challenges, and potential pathways for the pharma biotech sector to prioritise quality, ultimately benefiting both businesses and consumers.
The carrot and the stick: revitalising quality in the pharmaceutical industry
The pharmaceutical sector is at a critical juncture, facing immense pressure to enhance quality management systems and ensure the safety of medications
You may also like
Regulatory
NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development
Read moreThe discussion underscored the growing importance of aligning employee behaviours with compliance objectives, while also addressing the industry’s ongoing challenges around regulatory benchmarking and operational consistency
Trending Articles
You may also like
Regulatory
NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development
The discussion underscored the growing importance of aligning employee behaviours with compliance objectives, while also addressing the industry’s ongoing challenges around regulatory benchmarking and operational consistency
Regulatory
The foundations of pharmaceutical compliance for beginners
Whether you’re stepping into the pharmaceutical industry for the first time or pivoting into a compliance or quality assurance role after years of experience, mastering the fundamentals of quality and regulatory compliance is vital to your success—and to the success of your organisation